SCA
PDLI

SAC Capital Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

SAC Capital Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-19,823
Closed -$167K – 2197
2013
Q4 		$167K Buy
+19,823
New +$167K ﹤0.01% 1666

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SAC Capital Advisors's PDLI Position: Q1 2014 in Review

SAC Capital Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2014, closing a stake of 19,823 shares — an estimated $167K sold.

SAC Capital Advisors first reported a position in PDLI in Q4 2013 and held it in 1 quarter. The position peaked at $167K in Q4 2013. 233 funds tracked by Wall St. Rank hold PDLI as of Q1 2014.

  • SAC Capital Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 19,823 PDL BioPharma, Inc. shares in Q1 2014, an estimated $167K.
  • SAC Capital Advisors first reported a position in PDL BioPharma, Inc. in Q4 2013 and held it in 1 quarter.
  • SAC Capital Advisors's PDL BioPharma, Inc. position peaked at $167K in Q4 2013.
  • 233 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2014.

Based on SAC Capital Advisors's 13F filing for Q1 2014, filed 15 May 2014.